Gilead Sciences, Inc. reported 5 positions worth $1.65B for the quarter ended Jun 30, 2026, down 22.1% on the prior quarter. It opened 0 new positions, added to 1, trimmed 0 and exited 1. Its largest holding is Arcus Biosciences, Inc. at 58.8% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Trade Value | Weight |
|---|---|---|---|
| ASMB Assembly Biosciences, Inc. | +471.7K +10.5% | $12.96M | 8.3% |
| Holding | Change | Trade Value | Weight |
|---|---|---|---|
| ACLX GILEAD SCIENCES INC- CVR CONTINGENT VALUE RIGHT | -6.72M -100.0% | $771.68M | Exited |
No new positions this quarter.
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| ACLX GILEAD SCIENCES INC- CVR CONTINGENT VALUE RIGHT | -6.72M | $771.68M | 36.44% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | RCUS Arcus Biosciences, Inc. | Healthcare | 31.42M | $968.83M | 58.76% | 0 | 0.0% | Unchanged | 24.74% |
| 2 | LKFT Lakefront Biotherapeutics NV | Healthcare | 16.71M | $500.16M | 30.34% | 0 | 0.0% | Unchanged | 25.35% |
| 3 | ASMB Assembly Biosciences, Inc. | Healthcare | 4.98M | $136.77M | 8.3% | +471.7K | +10.5% | Added | 25.07% |
| 4 | KYTX Kyverna Therapeutics, Inc. | Healthcare | 4.13M | $36.76M | 2.23% | 0 | 0.0% | Unchanged | 6.7% |
| 5 | XLO Xilio Therapeutics, Inc. | Healthcare | 650.4K | $6.23M | 0.378% | 0 | 0.0% | Unchanged | 3.35% |
Tip. Select a row to see that position’s full history at Gilead Sciences.
As of its Q2 2026 13F filing, Gilead Sciences, Inc.’s five largest positions were Arcus Biosciences, Inc. (RCUS) at 58.8%, Lakefront Biotherapeutics NV (LKFT) at 30.3%, Assembly Biosciences, Inc. (ASMB) at 8.3%, Kyverna Therapeutics, Inc. (KYTX) at 2.2%, Xilio Therapeutics, Inc. (XLO) at 0.4% of the reported portfolio.
Gilead Sciences, Inc. reported a 13F portfolio worth $1.65B across 5 positions for Q2 2026. That is down 22.1% from the previous quarter.
Its largest purchases by value were Assembly Biosciences, Inc. ($12.96M). It opened 0 new positions.
Its largest sales by value were GILEAD SCIENCES INC- CVR CONTINGENT VALUE RIGHT ($771.68M). It exited 1 positions entirely.
From the Form 13F-HR reports Gilead Sciences, Inc. files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.